RADAR-CNS, a major new research programme supported by the Innovative Medicines Initiative (IMI), is developing new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology.
The project (RADAR-CNS: Remote assessment of disease and relapse – Central Nervous System) is jointly led by King’s College London and Janssen Pharmaceutica NV. It brings together researchers from 23 organisations across Europe, drawing on diverse expertise in clinical research, engineering, computer science, information technology, data analytics and health services.
In recent years, the quality and quantity of data that we can collect using wearable devices and smartphones has exploded. RADAR-CNS will exploit the huge potential of wearable technologies to improve the lives of the millions of people worldwide with chronic illnesses like epilepsy, depression and multiple sclerosis.
Professor Matthew Hotopf, King’s College London and the NIHR Maudsley Biomedical Research Centre
Watch our new video, where the project’s co-leaders – Professor Matthew Hotopf from King’s College London and Vaibhav Narayan from Janssen Pharmaceutica – explain what the programme will cover and why it is needed.
Visit the RADAR-CNS website to find out more.